CereVasc and LianMedical Partner to Bring eShunt System to Asian Markets

July 7, 2023—CereVasc, Inc. and LianMedical recently announced a partnership focused on bringing CereVasc’s eShunt system and related products to patients and providers in China, Hong Kong, Taiwan, and Macaw.

As stated in the press release, LianMedical is a medical device company headquartered in Shanghai, China, that is focused on accelerating the introduction of breakthrough medical technologies to markets in Asia.

CereVasc is a Massachusetts-based clinical-stage, medical device company developing treatments for neurological diseases. The eShunt system, which is CereVasc’s initial product, provides percutaneous transvenous-transdural access to the central nervous system to allow minimally invasive treatment for communicating hydrocephalus. The system includes an endovascularly implantable cerebral spinal fluid shunt and delivery components, which are designed to treat communicating hydrocephalus without invasive surgery.

Dan Levangie, President & CEO of CereVasc, commented in the press release, “We are very excited by the opportunity for our products to improve the standard of care for patients with hydrocephalus in these territories and believe we have identified the ideal partner in LianMedical to support these expansion efforts.”

Luxin Wang, CEO of LianMedical, added, “There is significant unmet clinical need in hydrocephalus treatment in Asia. The eShunt system is an innovation that can potentially revolutionize the standard of care and benefit thousands of patients. We are excited to partner with Dan and his team to capitalize on this significant opportunity.”

The eShunt system’s concept originated from Carl Heilman, MD, Neurosurgeon-in-Chief and Chair of Neurosurgery, and Adel Malek, MD, Chief of Neurovascular Surgery and Director of Endovascular Neurosurgery at Tufts Medical Center in Boston, Massachusetts.

The eShunt device is an investigational device and not available for sale in or outside the United States, advised CereVasc in the press release.